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Abstract: Recently, “ipilimumab,” an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
  monoclonal antibody, has been demonstrated to improve overall survival in metastatic   melanoma. 
“CTLA-4” is an immune-checkpoint molecule that downregulates pathways of T-cell activation. 
Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing 
the immune system to react to cancer cells. Due to its immune-based mechanism of action, 
  ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhance-
ment of antitumor specific immune response mediated by the weakening of self-tolerance 
mechanisms while exacerbating the development of autoimmune diseases and immune-related 
adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis.
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Introduction
“Ipilimumab” is a recombinant human immunoglobulin (Ig) G1 monoclonal antibody 
targeting the “cytotoxic T-lymphocyte antigen” (CTLA-4), a negative regulator of 
T-cell activation, expressed by activated T-cells as well as by T-regulatory cells.1
Both T-cell receptors cluster of differentiation (CD) 28 and CTLA-4 react with two 
ligands displayed on the cell surface by antigen-presenting cells, CD80 and CD86. 
CD28 and CTLA-4 function antagonistically; in fact, the interaction between CD28 
and either CD80 or CD86 enhances T-cell activation, proliferation, and interleukin-2 
(IL-2) production. In contrast, CTLA-4, which binds to CD80 and CD86 with greater 
affinity than to CD28, antagonizes T-cell activation by interfering with IL-2 secretion 
and IL-2-receptor expression. Ipilimumab, by binding CTLA-4, is able to block its 
interaction with CD80 or CD86 and allows for optimal interaction between T-cell CD28 
receptors and CD80/86, therefore resulting in optimal T-cell activation.1
Ipilimumab has demonstrated a significant benefit in improving overall survival 
(OS) in patients affected by metastatic melanoma in two Phase III trials, namely the 
MDX010-20 Phase III trial,2 which compared ipilimumab with a vaccine against 
glycoprotein 100, and the CA184-024 study,3 in which standard treatment (dacarba-
zine) was compared with dacarbazine plus ipilimumab.4 In the first study, ipilimumab 
demonstrated median OS of 10 months and patients that showed a long duration 
response or partial/complete response were subsequently treated with reinduction of 
ipilimumab when they had disease progression. In the second study, the addition of 
ipilimumab to dacarbazine significantly improved OS, with high OS rates at 1, 2, and 
3 years of follow-up. The results of these studies have been confirmed by data from an OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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expanded access program.5 Further, ipilimumab has shown to 
achieve unusually long-term responses in individual patients 
and a relatively higher response rate (from 10% to 15%) than 
that obtained with traditional drugs and/or B-raf inhibitors.6 
For all these reasons, ipilimumab has been approved for the 
treatment of metastatic melanoma at a regimen of 3 mg/kg 
intravenously every 3 weeks for four doses by the US Food 
and Drug Administration in first-line treatment and by the 
European Medicine Agency in second- and following lines 
of treatment.
Lastly, new monoclonal antibodies targeting CTLA-4, 
such as tremelimumab (Pfizer, New York, NY, USA) and 
nivolumab (Bristol-Myers Squibb, New York, NY, USA), 
also known as “MDX1106,” which block programmed cell 
death 1 (PD-1), have been developed for the treatment of 
metastatic melanoma. “PD-1” is a key immune-checkpoint 
receptor expressed by activated T-cells, similar to CTLA-4, 
that binds two different ligands: PD1-L1 and PD1-L2. This 
inhibits the cytokine production from and cytolytic activity 
of PD-1, and tumor cells can escape immune-system control 
and begin to grow without control. Monoclonal antibodies 
directed against PD-1 and PD1-L1 may be able to stimulate 
the cytotoxic activity of the immune system and to inhibit 
tumor growth. Published clinical trial results indicate that the 
toxicity profile of these drugs appears to be similar to that 
shown by ipilimumab.7
Immune-related adverse events
Treatment with the fully human anti-CTLA-4 monoclo-
nal antibody ipilimumab is typically associated with the 
onset of immune-related adverse events (irAEs) which are 
strongly related to its immune-based mechanism of action. 
CTLA-4 blockade removes CTLA4-mediated protection 
from autoimmunity, and it is responsible for a large spec-
trum of autoimmune–inflammatory side effects, classified 
as irAEs.8–10 A retrospective analysis of several ipilimumab 
Phase I–III trials in patients with advanced melanoma 
showed that irAEs occurred in about 64.2% of treated 
patients and resulted in death in ,1% of them.11 The most 
common immune-mediated effects were enterocolitis, der-
matitis, hepatitis, hypophysitis, and uveitis, which developed 
particularly during the induction phase. Time to resolution 
of irAEs varied from 4.3 to 7.7 weeks.12 However, recently, 
some evidence has indicated that ipilimumab-induced irAEs 
may be associated with clinical benefit,13,14 even in the adju-
vant setting in resected high-risk stage IIIC/IV melanoma 
patients.15 Nevertheless, these data need to be verified by 
further clinical trials, since other studies have shown no 
correlation between toxicity and efficacy.2,16
The correct management of irAEs involves prompt medi-
cal attention and the early administration of high-dose sys-
temic corticosteroids for grade 3 or 4 events. Bristol-Myers 
Squibb has developed specific guidelines to assist health-care 
professionals in the management of irAEs. Tables 1 and 2 
describe the common side effects of ipilimumab and their 
management.
Gastrointestinal toxicity
Among all ipilimumab-induced irAEs, those affecting the 
gastrointestinal (GI) tract (GI irAEs) are the most frequent. 
GI irAEs may present through a wide spectrum of clinical 
manifestations (usually defined during clinical trials accord-
ing to the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events v 3.017). Fever, weakness, abdom-
inal pain, or an increase in the number of bowel movements,   
hematochezia, nausea, and vomiting have been reported.12 
The most frequent GI side effect is diarrhea, characterized by 
watery/bloody stools, reported with a frequency of 20%–31% 
in the ipilimumab groups of the MDX010-20 Phase III trial, 
which led in 2011 to US Food and Drug Administration and 
European Medicines Agency approval of ipilimumab treat-
ment at the dosage of 3 mg/kg for metastatic melanoma. In 
that trial, diarrhea and other GI side effects were reported to 
occur 5 to 12 weeks after the first drug administration. The 
use of a specific protocol for toxicity management often led 
to the resolution of these side effects in a median time of 
about 4 weeks from onset.18 The careful monitoring of signs 
and symptoms that suggest GI irAE onset is of the utmost 
importance; at the beginning of treatment, all patients as 
well as caregivers should be trained to refer any changes in 
clinical condition, especially in bowel habits, to physicians 
as early as possible in order to allow timely treatment and 
avoid more serious, life-threatening complications such as 
bowel perforation and obstruction. Rarely, diarrhea may 
hide bowel ulceration or perforation; in fact, immune-related 
colitis usually involves a descending colon and can present 
as a weak pain and diarrhea.19 Histopathologic findings of 
biopsies obtained after the onset of diarrhea often reveal 
features of diffuse active colitis with infiltrates of neutrophils, 
lymphocytes, and plasma cells in the lamina propria, together 
with crypt abscesses and mucosal ulcerations.20
In patients reporting low-grade GI toxicity (mild to moder-
ate diarrhea or colitis), a symptomatic treatment consisting of 
loperamide, fluids, and electrolyte replacement, together with OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Table 1 Most common side effects of ipilimumab and their grades
Treatment- 
related AE
Grade 1 Grade 2 Grade 3 Grade 4
Skin toxicity Mild to moderate  
localized rash or pruritus; 
papules/pustules covering  
,10%–30% of body  
surface
Nonlocalized rash  
(diffuse, #50% of skin surface)
intense or widespread rash .30%;  
skin sloughing ,10%–30%  
of body surface; epidermal  
or mucus membrane detachment
Stevens–Johnson syndrome, 
toxic epidermal necrolysis, 
or rash complicated by full-
thickness dermal ulceration, 
or necrotic, bullous, or 
hemorrhagic manifestations
Diarrhea increase of ,4 stools  
per day over baseline;  
mild increase in ostomy  
output compared with  
baseline
increase of 4–6 stools per day  
over baseline; IV fluids indicated  
,24 hours; moderate increase  
in ostomy output compared to  
baseline; not interfering with ADL
increase of $7 stools per day over  
baseline; incontinence; IV fluids  
$24 hours; hospitalization; severe  
increase in ostomy output compared  
with baseline; interfering with ADL
Life-threatening consequences   
(eg, hemodynamic collapse)
Liver toxicity Asymptomatic or mild  
symptoms; clinical or  
diagnostic observations  
only; intervention  
not indicated
AST or ALT .2.5 to #5.0× ULN  
and/or total bilirubin .1.5  
to #3.0× ULN
AST or ALT .5× ULN and/or  
total bilirubin .3.0× ULN
Moderate to severe 
encephalopathy with abnormal 
plasma levels of ammonia, 
bilirubin, lactic dehydrogenase, 
and alkaline phosphatase
endocrine  
toxicity
Asymptomatic;  
clinical or diagnostic  
observations only;  
intervention not indicated
Moderate symptoms;  
medical intervention  
indicated
Severe symptoms;  
hospitalization indicated
Adrenal crisis: severe 
dehydration, hypotension, 
or shock. Life-threatening 
consequences
Abbreviations: Ae, adverse event; ADL, activities of daily living; ALT, alanine transaminase; AST, aspartate aminotransferase; iv, intravenous; ULN, upper limits of normal.
Table 2 Management of ipilimumab-related side effects
Side effect Grade 1 Grade 2 Grade 3 Grade 4
Skin  
toxicity
Antihistamines and topical  
corticosteroids; if no  
response, consider oral  
corticosteroids
Antihistamines and topical  
corticosteroids if no response,  
consider oral corticosteroids
High-dose systemic  
corticosteroid therapy
High-dose systemic 
corticosteroid therapy; 
antibiotics if indicated and 
definitive discontinuation 
of ipilimumab
Diarrhea Anti-diarrhea drugs, 
loperamide and  
diphenoxylate
Patient hydration
Anti-diarrhea drugs
Loperamide and diphenoxylate
Patient hydration
Hospitalization, patients  
hydration and systemic  
corticosteroids
Hospitalization, patient 
hydration, and systemic 
corticosteroids
Definitive discontinuation 
of ipilimumab
Liver  
toxicity
Monitoring of LFTs withhold ipilimumab dose and check  
LFTs every day for 3 consecutive  
days; if LFT improvement to grade 1,  
resume routine monitoring  
of LFTs and continue ipilimumab
if no improvement in the LFTs,  
administer corticosteroid  
treatment and skip the next  
ipilimumab dose until event  
resolves
withhold ipilimumab dose  
and check LFTs every day  
for 3 consecutive days; if LFT  
improvement to grade 1,  
resume routine monitoring of  
LFTs and continue ipilimumab
if no improvement in LFTs,  
administer corticosteroid  
treatment and skip the next dose  
of ipilimumab until event resolves
High dose of intravenous 
corticosteroids
Definitive discontinuation
of ipilimumab
endocrine  
toxicity
Abnormal endocrine workup,  
grade 1 or 2 endocrine  
toxicity without adrenal crisis  
may resolve spontaneously
if no spontaneous resolution,  
consider low–moderate dose  
of systemic corticosteroids
Consider temporary  
ipilimumab suspension
Patients with symptoms suggestive  
of hypophysitis require prompt  
corticosteroid therapy
Temporary ipilimumab suspension
intravenous corticosteroids
Hormone replacement
Hydration
electrolyte replacement
Temporary ipilimumab  
suspension
intravenous 
corticosteroids
Hormone replacement
Hydration
electrolyte replacement
Definitive discontinuation
of ipilimumab
Abbreviation: LFT, liver function tests.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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the close monitoring of signs and symptoms, is   recommended. 
The next scheduled dose of ipilimumab should be omitted 
until resolution of the symptoms or the achievement of grade 1 
toxicity.21 In the case of rectal bleeding, persistent grade 2 
toxicity or higher diarrhea, a complete laboratory/endoscopic 
workup should be performed in order to rule out other causes 
of colitis, such as infection or inflammatory bowel disease; 
corticosteroid administration should be considered and some 
researchers even propose treatment with oral diphenoxylate 
hydrochloride, atropine sulfate, and budesonide 9 mg once 
per day.22 When severe diarrhea or colitis occurs (grade 3–4), 
treatment with ipilimumab must be permanently discontin-
ued, and appropriate therapy with high-dose intravenous 
steroids (methylprednisolone 2 mg/kg/day) started immedi-
ately, together with adequate fluid/electrolyte replacement. 
Maintenance oral prednisolone (1–2 mg/kg/day) may be 
employed. Once improvement of symptoms and clinical con-
dition is achieved, a slow tapering of corticosteroids can be 
initiated according to the clinician’s judgment; it is noteworthy 
to underline the extreme importance of performing a gradual 
weaning from steroids, over a period of at least 1 month, in 
order to avoid early recurrence.12
Prophylactic use of budesonide 9 mg/day during treatment 
with ipilimumab has been tested in a Phase II trial performed 
by Wolchok et al.19 However, the drug was not recommended 
since it did not demonstrate efficacy in preventing the onset 
of GI toxicity. In rare cases of steroid-resistant GI irAEs, 
treatment with a single dose of the immunosuppressive agent 
infliximab at 5 mg/kg in addition to corticosteroids can be 
considered unless the sepsis or GI perforation is suspected; 
to avoid early recurrence, steroid administration should be 
tapered over 45–60 days.22
immune-related hepatotoxicity
Hepatic irAEs were reported with a low frequency (about 3%) 
in patients treated with ipilimumab in the MDX010-20 clini-
cal trial, with an average time to onset of 3 to 9 weeks for 
serious events and a time to resolution – with prompt treat-
ment according to specific guideline recommendations – of 
about 2 weeks.
Usually, ipilimumab-induced hepatitis is characterized by 
an asymptomatic worsening of liver function tests (LFTs), 
such as an elevation of alanine transaminase (ALT)/aspartate 
aminotransferase (AST) or bilirubin levels, although fatigue 
and fever also occur.7 A complete workup to rule out viral 
hepatitis, disease progression (liver metastases), or other 
drug-related toxicity must be performed. Liver biopsies 
have been reported to show the hallmarks of both “acute” 
hepatitis, with necrosis and perivenular infiltrate (damage of 
hepatocytes) and “biliary” hepatitis (predominant damage of 
bile ducts); imaging findings in cases of serious liver damage 
revealed the presence of hepatomegaly, periportal edema and 
diffuse low-attenuation liver parenchyma.23
Because of the typical asymptomatic onset of immune-
  related hepatitis, LFTs must be assessed before each ipilimumab 
administration and carefully monitored subsequently.
If AST/ALT levels present in the range of .5 to ,8× 
above the upper limits of normal levels (ULN) or total bili-
rubin is in the a range of .3 to ,5× above ULN, the next 
dose of ipilimumab should be omitted and LFTs should be 
monitored until resolution of the toxicity; once AST/ALT 
levels return to ,5× over ULN and total bilirubin ,3× over 
ULN, treatment with ipilimumab can be restarted with the 
next scheduled dose.21 In the case of AST/ALT levels, eleva-
tion of .8× over ULN means that ipilimumab treatment 
must be permanently discontinued and intravenous high-
dose corticosteroid treatment must be immediately started 
(methylprednisolone 2 mg/kg/day or equivalent) for 24–48 
hours, followed by oral prednisone 1–2 mg/kg/day; LFTs 
must be monitored daily until AST/ALT levels begin to drop. 
Once LFT improvement is achieved, a slow steroid tapering 
could be considered, according to clinical judgment, over 
a period of at least 30 days in order to avoid recurrence.22 
Ipilimumab-induced hepatitis is usually highly responsive to 
adequate steroid administration, but some cases of refractory 
hepatotoxicity have been reported. If serum transaminase 
levels do not decrease within about 48 hours after starting 
steroids, the administration of oral mycophenolate mofetil 
could be considered; infliximab should be avoided in these 
patients because of its hepatotoxicity.24 Interestingly, Chmiel 
at al reported a case of a severe ipilimumab-induced hepati-
tis refractory to steroids and mycophenolate mofetil, which 
was resolved with the administration of antithymocyte 
globulin.25
Skin toxicity
Dermatologic toxicity (DT) is the most common ipilimumab-
induced irAE, but it is rarely of severe grade, being classi-
fied in the majority of the cases as grade 1–2. DT generally 
appears after 2–4 weeks of treatment.21,24 Patients should be 
advised to report any skin changes and to monitor for rash 
and pruritus appearance.19 Maculopapular rashes occur in 
10%–50% of patients treated with ipilimumab, with or without 
pruritus.26 For patients with nonlocalized rash or diffuse rash 
over less than 50% of the skin, ipilimumab can be withheld 
and topical or systemic corticosteroids such as betamethasone OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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0.1%, hydrocortisone 1%, or urea-based topical therapies 
with   antipruritic agents can be dispensed.1 Sun avoidance 
and the use of broad-spectrum sunscreen is recommended 
prophylactically. The use of oral antihistamines may also 
assist with pruritus.27 Ipilimumab should be interrupted for 
grade 3 dermatitis until the rash returns to grade 1–2, while 
grade 4 toxicity requires hospitalization.22 “Stevens–Johnson 
syndrome,” defined as rash complicated by dermal   ulceration, 
necrotic, bullous or hemorrhagic manifestations, and toxic 
epidermal necrolysis, has sometimes been observed.22 In 
this case, ipilimumab should be permanently discontin-
ued and systemic corticosteroids must be administered at 
1–2 mg/kg/day of prednisone equivalent.21 Other reported 
skin reactions include prurigo, acneiform rash, lichenoid 
exanthema, pyoderma gangrenosum-like ulcerations, skin 
toxicity in the irradiated area, photosensitivity, and a drug 
rash with eosinophilia and systemic symptoms.26   Interestingly, 
melanoma-associated hypopigmentation has been reported 
and postulated to be prognostically favorable.26
endocrine Aes
Although uncommon, “endocrinopathies” are a group of tox-
icities induced by ipilimumab and may include hypopituitar-
ism, hypophysitis, hypothyroidism, and adrenal insufficiency.27 
In the MDX010-20 trial, endocrine irAEs occurred in 4%–8% 
of all patients treated with   ipilimumab.4   “Hypophysitis” is a 
rare, yet serious complication of ipilimumab treatment, with 
an incidence of up to 17%.28 Symptoms include loss of libido, 
fatigue, headache, memory difficulties, dizziness, vision 
changes, and constipation. Symptoms of hypophysitis usu-
ally develop after 6 weeks of treatment and, when suspected, 
a complete workup, including serum potassium, sodium, 
morning cortisol, luteinizing hormone, follicle-stimulating 
hormone, testosterone, insulin-like growth factor-1 and free 
thyroxine dosage, as well as brain magnetic resonance imag-
ing to exclude brain metastases, is mandatory.26 A report 
on nine patients treated with ipilimumab who developed 
autoimmune hypophysitis showed that eight of them had a 
correlative increase in pituitary size on imaging. Ipilimumab 
should be stopped in patients with evidence of autoimmune 
hypophysitis and be administered physiological hormone 
replacements, with hydrocortisone, thyroxine, and sexual 
hormones. A short course of high-dose steroids (prednisone 
at dose of 1–2 mg/kg/day) may improve pituitary function. 
If suspicion of an adrenal crisis subsists, an endocrinolo-
gist should be consulted and a stress dose of intravenous 
  steroids such as dexamethasone 4 mg every 6 hours should 
be administered; a gonadal and thyroid hormone replacement, 
if required, should be performed.27 Longer-term management 
may involve   tapering of steroids over a minimum of 4 weeks; 
however, many patients will require steroid replacement for 
longer periods. Ipilimumab may be re-instituted after reso-
lution of grade 1–2 endocrinopathies, but, since the risk of 
further complications is unknown, its restart is not recom-
mended in more severe cases. Recently, however, patients 
with hypophysitis needing hormone replacement have been 
retreated with ipilimumab without worsening side effects.27
Other immune-related Aes
Ophthalmological side effects are very rare and have been 
reported in less than 1% of treated patients. These events 
usually resolve within a week, but treatment with steroid eye 
drops may be required, and systemic corticosteroids in the 
more severe cases, such as uveitis, iritis, or episcleritis, are 
strongly recommended.27
Neurological toxicity such as Guillain–Barré syndrome, 
sensory or motor neuropathy, and myasthenia gravis have 
been reported in less than 1% of patients. Treatment with 
corticosteroids (prednisone 1–2 mg/kg/day) over 4 weeks in 
concomitance with cessation of ipilimumab is indicated for 
grade 3–4 neuropathy, while lower-grade neuropathy can be 
managed by holding the next dose of ipilimumab. Severe to 
fatal immune-related neuropathies have been rarely reported, 
and they were observed in less than 2% of patients receiving 
ipilimumab in the MDX010-20 study.12
Respiratory tract irAEs, such as alveolitis, atypical pneu-
monia, fatal acute respiratory distress syndrome, pulmonary 
granulomatosis, sarcoidosis,29–31 and adverse reactions affect-
ing the renal tract have very rarely been observed; when they 
do occur, they have significant, often life-threatening, clinical 
implications. Sometimes the radiological signs of sarcoidosis 
can be confused with pulmonary metastases resulting in an 
inadequate change of therapy. Both conditions must be treated 
with high-dose steroids.31
Conclusion
The evidence that ipilimumab significantly improves OS in 
advanced melanoma patients has led to its approval for the 
treatment of pretreated metastatic melanoma. Ipilimumab, 
which inhibits CTLA-4, activates and prolongs the immune 
response, but this effect is associated with a high incidence 
of autoimmune pathologies, which are commonly manage-
able with steroids and other supportive cares. However, 
the efficacy of ipilimumab in controlling the disease, as 
documented in a number of clinical trials, should be taken 
into account and its suspension strongly discouraged. The OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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adequate management of the immune-related side effects 
should be addressed by a multidisciplinary team with the aim 
of avoiding suspension or under dosage of the drug.
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